Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy

Kidney Int. 2016 Jun;89(6):1401-2. doi: 10.1016/j.kint.2016.02.022.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Calcineurin Inhibitors / therapeutic use
  • Cyclophosphamide / pharmacology*
  • Cyclophosphamide / therapeutic use
  • Drug Resistance*
  • Drug Therapy, Combination / methods
  • Female
  • Glomerulonephritis, Membranous / drug therapy*
  • Glomerulonephritis, Membranous / immunology
  • Glomerulonephritis, Membranous / urine
  • Glucocorticoids / pharmacology
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / immunology
  • Nephrotic Syndrome / urine
  • Phospholipases A2
  • Prednisolone / pharmacology
  • Prednisolone / therapeutic use
  • Proteinuria / drug therapy
  • Proteinuria / immunology
  • Proteinuria / urine
  • Receptors, Phospholipase A2 / immunology*
  • Recurrence
  • Respiratory Tract Infections / etiology
  • Tacrolimus / pharmacology
  • Tacrolimus / therapeutic use
  • Treatment Outcome
  • Young Adult

Substances

  • Calcineurin Inhibitors
  • Glucocorticoids
  • Immunosuppressive Agents
  • Receptors, Phospholipase A2
  • Cyclophosphamide
  • Prednisolone
  • Phospholipases A2
  • Tacrolimus